High Level of Adherence to Alirocumab and Concomitant Background Treatments for Patients With Heterozygous Familial Hypercholesterolemia in the ODYSSEY Open-Label Extension Study

被引：0
|
作者：
Farnier, Michel A.
Hovingh, G. Kees
Langslet, Gisle
Dufour, Robert
Baccara-Dinet, Marie T.
Din-Bell, Chantal
Manvelian, Garen
Guyton, John R.
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
PCSK9; Adherence; Cholesterol-lowering drugs; Hyperlipidemia; LDL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15057
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
    John J. P. Kastelein
    Jennifer G. Robinson
    Michel Farnier
    Michel Krempf
    Gisle Langslet
    Christelle Lorenzato
    Daniel A. Gipe
    Marie T. Baccara-Dinet
    Cardiovascular Drugs and Therapy, 2014, 28 : 281 - 289
  • [32] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
    Kastelein, John J. P.
    Robinson, Jennifer G.
    Farnier, Michel
    Krempf, Michel
    Langslet, Gisle
    Lorenzato, Christelle
    Gipe, Daniel A.
    Baccara-Dinet, Marie T.
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (03) : 281 - 289
  • [33] Alirocumab in high-risk patients: Observations from the open-label expanded use program
    Glueck, Charles J.
    Brown, Alan
    Goldberg, Anne C.
    McKenney, James M.
    Kantaros, Louis
    Stewart, John
    Elassal, Joseph
    Koren, Andrew
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 662 - 668
  • [34] Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients
    Genovese, Mark
    Fay, Jonathan
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    van Hoogstraten, Hubert
    Graham, Neil
    Boddy, Alex
    Simon, Abraham
    Martincova, Renata
    Burmester, Gerd
    Fiore, Stefano
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 895 - 896
  • [35] Interim analysis: Open-label extension study of leniolisib for patients with APDS
    Rao, V. Koneti
    Kulm, Elaine
    Sediva, Anna
    Plebani, Alessandro
    Schuetz, Catharina
    Shcherbina, Anna
    Dalm, Virgil A.
    Trizzino, Antonino
    Zharankova, Yulia
    Webster, Sharon
    Orpia, Alanvin
    Koeurorholz, Julia
    Lougaris, Vassilios
    Rodina, Yulia
    Radford, Kath
    Bradt, Jason
    Relan, Anurag
    Holland, Steven M.
    Lenardo, Michael J.
    Uzel, Gulbu
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (01) : 265 - 274.e9
  • [36] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
    Genovese, M. C.
    Fay, J.
    Beyer, D.
    Iglesias-Rodriguez, M.
    Simon, A.
    Martincova, R.
    Burmester, G. R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S69 - S70
  • [37] Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
    Genovese, Mark C.
    Fay, Jon
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    Graham, Neil
    Boddy, Alex
    Simon, J-Abraham
    Martincova, Renata
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [38] Qualitative Perceptions of Dapivirine VR Adherence and Drug Level Feedback Following an Open-Label Extension Trial
    Naidoo, Kalendri
    Mansoor, Leila E.
    Katz, Ariana W. K.
    Garcia, Morgan
    Kemigisha, Doreen
    Morar, Neetha S.
    Zimba, Chifundo C.
    Chitukuta, Miria
    Reddy, Krishnaveni
    Soto-Torres, Lydia
    Naidoo, Sarita
    Montgomery, Elizabeth T.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (04) : E90 - E96
  • [39] Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
    Nam, Chang-Wook
    Kim, Dong-Soo
    Li, Jianyong
    Baccara-Dinet, Marie T.
    Li, Ivy
    Kim, Ji-Hyun
    Kim, Chong-Jin
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (06): : 1252 - +
  • [40] Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial
    Moriarty, Patrick M.
    Thompson, Paul D.
    Cannon, Christopher P.
    Guyton, John R.
    Bergeron, Jean
    Zieve, Franklin J.
    Bruckert, Eric
    Jacobson, Terry A.
    Baccara-Dinet, Marie T.
    Zhao, Jian
    Donahue, Stephen
    Ali, Shazia
    Manvelian, Garen
    Pordy, Robert
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (01) : 88 - +
12345